Related Experiment Video

Updated: Jul 24, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

DNA restriction fragment length polymorphisms as markers of familial coronary heart disease

W H Price1, S W Morris, A H Kitchin

  • 1University Department of Medicine, Western General Hospital, Edinburgh.

Lancet (London, England)
|June 24, 1989
PubMed

Insights

Men with a family history of coronary heart disease (CHD) and specific gene variants are at significantly higher risk. These genetic factors, linked to apolipoprotein genes, explain a substantial portion of CHD prevalence.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Epidemiology

Background:

  • Family history is a known risk factor for coronary heart disease (CHD).
  • Genetic predispositions, particularly involving apolipoprotein genes, may influence CHD risk.
  • Restriction fragment length polymorphisms (RFLPs) can identify genetic variations associated with disease.

Purpose of the Study:

  • To investigate the association between family history of CHD, specific RFLPs, and CHD prevalence in men.
  • To determine the contribution of minor alleles of RFLPs near apo AI and apo CIII genes to CHD risk.

Main Methods:

  • Case-control study analyzing 713 men aged 30-59.
  • Genotyping for 4 RFLPs (XmnI, PstI, MspI, SacI) using restriction enzymes.
  • Statistical analysis of CHD prevalence based on family history and RFLP genotypes.

Main Results:

  • Men with a family history of CHD were twice as likely to have CHD.
  • Minor alleles of RFLPs near apo AI/apo CIII genes significantly increased CHD prevalence by 234% in men with a family history.
  • These RFLP associations accounted for approximately 20% of total CHD in the population.

Conclusions:

  • Specific minor alleles of RFLPs in the apo AI/apo CIII region are strongly associated with increased CHD risk, particularly in men with a family history.
  • These genetic variants play a significant role in the development of coronary heart disease.
  • The findings highlight the importance of genetic screening for CHD risk assessment.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Restriction Enzymes01:11

Restriction Enzymes

Restriction enzymes are bacterial enzymes used to cut DNA in a sequence-specific manner. To cleave DNA, they bind to specific palindromic sequences called restriction sites. Such palindromic DNA sequences or inverted repeats are commonly found in regions of functional significance, such as the origin of replication, gene operator sites, and regions containing transcription termination signals.
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...